The CAR-T cancer therapy called Carvykti, made by Johnson & Johnson and Legend Biotech, reduced the risk of relapse by 74% compared to standard treatment in patients with multiple myeloma, according to results from a Phase 3 study that leaked online Tuesday night.
The magnitude of the patient benefit reported from the study called CARTITUDE-4 is much better than expected, and if cleared by regulators, will likely persuade doctors to use the personalized cell therapy earlier in the course of treatment of multiple myeloma.
Another CAR-T therapy for multiple myeloma, called Abecma, reduced the risk of relapse by 51% compared to standard treatment in a similar Phase 3 study published last February. Abecma is made by Bristol Myers Squibb and 2Seventy Bio.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
